Schuster Julius, Mundhenke Christin, Nordsieck Hannah, Pouchieu Camille, Pourtau Line, Hahn Andreas
Leibniz University Hannover, Institute of Food and One Health, Germany.
Activ'Inside, Beychac et Caillau, France.
Sleep Med X. 2025 Jul 9;10:100147. doi: 10.1016/j.sleepx.2025.100147. eCollection 2025 Dec 15.
Natural interventions for sleep disturbances, such as saffron extract, are gaining scientific and clinical interest. This 3-arm, randomized, double-blind, placebo-controlled trial examined the effect of a standardized saffron extract (Safr'Inside™) on sleep, stress, and other associated psychological outcomes in 165 adults reporting moderate insomnia.
Participants received 30 mg, 20 mg saffron extract, or placebo for 4 weeks. The primary endpoint was the change in insomnia symptoms (Athens Insomnia Scale, AIS). Secondary outcomes were the Single-Item Sleep Quality Scale (SQS), Perceived Stress Scale (PSS), Patient Health Questionnaire-4 (PHQ-4), Positive and Negative Affect Schedule (PANAS), Epworth Sleepiness Scale (ESS), and World Health Organization Quality of Life (WHOQOL). Analyses followed an intention-to-treat (ITT) approach, with per-protocol (PP) confirmation.
Among 150 completers, saffron extract led to a greater reduction in insomnia symptoms (AIS) than the placebo (between-group adjusted mean difference = -0.95 [95 % CI: -1.79, -0.11], < .05). In secondary analyses, sleep quality (SQS) improved significantly after 3 weeks and was sustained at week 4 in both saffron groups compared to placebo (30 mg vs placebo: = 0.82 [95 % CI: 0.22, 1.41], = .004; 20 mg vs placebo: = 1.02 [0.43, 1.62], < .001). Perceived stress (PSS) was significantly reduced with 30 mg or 20 mg saffron extract compared to placebo (30 mg vs placebo: = -1.87 [95 % CI: -3.23, -0.53], = .01; 20 mg vs placebo: = -1.89 [95 % CI: -3.22, -0.52], = .04). Some improvement in psychological symptoms (PHQ-4) was also observed with 30 mg saffron extract compared to placebo ( = -0.79 [-1.40, -0.18], = .03). All other measures showed no significant differences. No serious adverse events occurred.
Four weeks of 20 or 30 mg saffron extract may reduce insomnia and stress in middle-aged adults. Future research should assess longer interventions and explore which subgroups benefit most from saffron extract.
藏红花提取物等针对睡眠障碍的自然干预措施正引起科学界和临床界的关注。这项三臂、随机、双盲、安慰剂对照试验研究了标准化藏红花提取物(Safr'Inside™)对165名报告有中度失眠的成年人的睡眠、压力及其他相关心理指标的影响。
参与者接受30毫克、20毫克藏红花提取物或安慰剂,为期4周。主要终点是失眠症状的变化(雅典失眠量表,AIS)。次要结果包括单项睡眠质量量表(SQS)、感知压力量表(PSS)、患者健康问卷-4(PHQ-4)、正负性情绪量表(PANAS)、爱泼沃斯嗜睡量表(ESS)以及世界卫生组织生活质量量表(WHOQOL)。分析采用意向性分析(ITT)方法,并进行符合方案(PP)确认。
在150名完成试验者中,藏红花提取物比安慰剂能更显著地减轻失眠症状(AIS)(组间调整后均值差异=-0.95 [95%CI:-1.79,-0.11],P<.05)。在次要分析中,与安慰剂相比,两个藏红花组在3周后睡眠质量(SQS)均有显著改善,并在第4周得以维持(30毫克组与安慰剂组相比:β=0.82 [95%CI:0.22,1.41],P=.004;20毫克组与安慰剂组相比:β=1.02 [0.43,1.62],P<.001)。与安慰剂相比,30毫克或20毫克藏红花提取物能显著降低感知压力(PSS)(30毫克组与安慰剂组相比:β=-1.87 [95%CI:-3.23,-0.53],P=.01;20毫克组与安慰剂组相比:β=-1.89 [95%CI:-3.22,-0.52],P=.04)。与安慰剂相比,30毫克藏红花提取物在心理症状(PHQ-4)方面也有一定改善(β=-0.79 [-1.40,-0.18],P=.03)。所有其他指标均无显著差异。未发生严重不良事件。
20或30毫克藏红花提取物服用四周可能减轻中年成年人的失眠和压力。未来研究应评估更长时间的干预措施,并探索哪些亚组从藏红花提取物中获益最大。